The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
The partners will also collaborate on a study, to be peer reviewed, that will evaluate how insurance coverage of WGS affects patient care and healthcare costs.
Amid increasing spending on genetic testing, there are more opportunities for bad actors to implement interstate, fraudulent billing schemes, according to OIG.
